Our findings not only suggest a potential mechanism leading to tRF-27 accumulation in trastuzumab-resistant HER2-positive breast cancer cells, but also provide a possible method to alleviate trastuzumab resistance in clinical treatment. This evidence concerns the gene ERBB2 and breast carcinoma.